Halozyme Therapeutics Increases Revenue Estimates Through 2025 and Beyond with New Acquisition Halozyme Therapeutics has raised its revenue estimates for 2025 and set ambitious financial guidance for 2026, driven by innovative acquisitions and strong royalty growth.

Halozyme Therapeutics Increases Revenue Estimates Through 2025 and Beyond with New Acquisition #United_States #San_Diego #Halozyme #Therapeutics #ENHANZE

Halozyme and Takeda Forge Partnership to Elevate Vedolizumab Treatment Accessibility Globally Halozyme and Takeda have signed an exclusive global deal to enhance the delivery of vedolizumab, leveraging Halozyme's innovative ENHANZE technology for better patient outcomes.

Halozyme and Takeda Forge Partnership to Elevate Vedolizumab Treatment Accessibility Globally #United_States #San_Diego #Halozyme #ENHANZE #Vedolizumab

U.S. FDA Grants Approval for RYBREVANT FASPRO to Treat Advanced Lung Cancer The FDA has approved RYBREVANT FASPRO, a new treatment for advanced EGFR-mutated non-small cell lung cancer, enhancing administration efficiency.

U.S. FDA Grants Approval for RYBREVANT FASPRO to Treat Advanced Lung Cancer #United_States #San_Diego #Halozyme #ENHANZE #RYBREVANT

Halozyme to Showcase Innovations at 8th Annual Evercore Healthcare Conference Halozyme Therapeutics, Inc. reveals Dr. Helen Torley will present at the Evercore Healthcare Conference, highlighting innovative drug delivery technologies.

Halozyme to Showcase Innovations at 8th Annual Evercore Healthcare Conference #United_States #San_Diego #Halozyme #ENHANZE #Hypercon

Halozyme Therapeutics Unveils $650 Million Convertible Notes Offering Due 2031 and 2032 Halozyme Therapeutics, Inc. announces its $650 million offering of convertible senior notes, maturing in 2031 and 2032, aimed at funding future projects.

Halozyme Therapeutics Unveils $650 Million Convertible Notes Offering Due 2031 and 2032 #United_States #San_Diego #Convertible_Notes #Halozyme_Therapeutics #ENHANZE

Halozyme Reports Impressive Financial Growth and Raises Guidance for 2025 Halozyme Therapeutics shares quarterly results showing significant revenue growth, raising 2025 guidance with remarkable achievements in drug delivery technology.

Halozyme Reports Impressive Financial Growth and Raises Guidance for 2025 #United_States #San_Diego #Halozyme #ENHANZE #Elektrofi

Halozyme Therapeutics Set to Engage Investors at Key Upcoming Conferences Halozyme Therapeutics will actively engage with investors at notable upcoming conferences, showcasing their innovations and strategic goals in the biopharmaceutical space.

Halozyme Therapeutics Set to Engage Investors at Key Upcoming Conferences #United_States #San_Diego #Halozyme #ENHANZE #Dr._Helen_Torley

Halozyme Therapeutics Reports Significant Financial Growth for Q2 2025 with Raised Guidance Halozyme Therapeutics shows remarkable revenue growth in Q2 2025, prompting an upward revision of its financial guidance for the year, reflecting confidence and market demand.

Halozyme Therapeutics Reports Significant Financial Growth for Q2 2025 with Raised Guidance #USA #San_Diego #Halozyme #ENHANZE #Drug_Delivery

Halozyme Therapeutics to Engage in Key Investor Conferences in June 2025 Halozyme Therapeutics announces participation in two major investor conferences, aiming to connect and engage with potential investors on upcoming advancements in healthcare.

Halozyme Therapeutics to Engage in Key Investor Conferences in June 2025 #United_States #San_Diego #Halozyme #ENHANZE #Dr._Helen_Torley

Bristol Myers Squibb Gains EU Approval for Subcutaneous Opdivo® with ENHANZE® Technology Halozyme announces that Bristol Myers Squibb's Opdivo® has received EU approval for subcutaneous delivery, enhancing treatment options for cancer patients.

Bristol Myers Squibb Gains EU Approval for Subcutaneous Opdivo® with ENHANZE® Technology #United_States #California #Bristol_Myers_Squibb #ENHANZE #OPDIVO

Halozyme Therapeutics Increases 2025 Financial Projections Following Strong Q1 Results Halozyme Therapeutics reports remarkable first-quarter 2025 results, prompting an increase in its financial guidance, reflecting significant growth across various metrics.

Halozyme Therapeutics Increases 2025 Financial Projections Following Strong Q1 Results #United_States #San_Diego #Halozyme_Therapeutics #ENHANZE #rHuPH20

European Commission Grants Approval for RYBREVANT® with ENHANZE® for Lung Cancer Treatment Halozyme Therapeutics announces that the European Commission has granted marketing authorization for RYBREVANT® (amivantamab) co-formulated with ENHANZE® for treating advanced non-small cell lung cancer with specific mutations.

European Commission Grants Approval for RYBREVANT® with ENHANZE® for Lung Cancer Treatment #United_States #San_Diego #Halozyme #ENHANZE #RYBREVANT

Positive Opinion for Opdivo® Subcutaneous Formulation by CHMP: A Breakthrough in Cancer Therapy Halozyme Therapeutics announces that the CHMP has given a positive opinion for the subcutaneous formulation of Opdivo® (nivolumab) for treating solid tumors, enhancing patient treatment options significantly.

Positive Opinion for Opdivo® Subcutaneous Formulation by CHMP: A Breakthrough in Cancer Therapy #United_States #San_Diego #Halozyme #ENHANZE #OPDIVO

Halozyme to Showcase Innovations at TD Cowen Healthcare Conference Halozyme Therapeutics will participate in the TD Cowen 45th Annual Healthcare Conference led by CEO Dr. Helen Torley, discussing key advancements.

Halozyme to Showcase Innovations at TD Cowen Healthcare Conference #United_States #San_Diego #Halozyme_Therapeutics #ENHANZE #Dr._Helen_Torley

Halozyme Achieves Record Revenue in 2024, Surpassing Financial Expectations Halozyme Therapeutics closes 2024 with record revenue exceeding $1 billion, driven by strong performance in royalty revenues and product sales.

Halozyme Achieves Record Revenue in 2024, Surpassing Financial Expectations #USA #San_Diego #Halozyme #biotechnology #ENHANZE

European Support for Innovative Lung Cancer Treatment with RYBREVANT® and ENHANZE® The CHMP has endorsed a combination treatment of RYBREVANT® and ENHANZE® for advanced EGFR-mutated lung cancer, setting a quick administration path.

European Support for Innovative Lung Cancer Treatment with RYBREVANT® and ENHANZE® #USA #San_Diego #Halozyme #ENHANZE #RYBREVANT

Takeda's Regulatory Approval for HYQVIA®: A Milestone for Patients in Japan Takeda has gained regulatory approval for HYQVIA® in Japan, offering a new treatment option for patients with agammaglobulinemia and hypogammaglobulinemia, reducing the frequency of doses.

Takeda's Regulatory Approval for HYQVIA®: A Milestone for Patients in Japan #Japan #Tokyo #HYQVIA #ENHANZE #Takeda